Therapy News and Research

RSS

Ikaria's INOmax approved in Australia

Ikaria Holdings, Inc., through its subsidiary INO Therapeutics LLC, announced today that it has received approval from Australia's regulatory body, the Therapeutic Goods Administration (TGA), for INOmax (nitric oxide) for inhalation.

27 Nov 2007

Cryoablation for bone cancer tumors reduces pain, study shows

Cryoablation, a procedure most commonly associated with destroying kidney and prostate tumors by freezing them, has been shown to offer durable pain relief of cancer that has spread to bone.

27 Nov 2007

Study looks at progesterone for Alzheimer's

The first study on progesterone and Alzheimer's disease has found no clear preventive benefit for the widely prescribed hormone in an animal model.

27 Nov 2007

Certain infusion therapy after heart attack does not appear to be beneficial, may cause harm

Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), according to a study in the November 28 issue of JAMA: The Journal of the American Medical Association.

27 Nov 2007

Scientists create mouse resistant to cancer

A mouse resistant to cancer, even highly-aggressive types, has been created by researchers at the University of Kentucky.

27 Nov 2007

Blood-vessel blocker aids cancer-killing virus

Cancer-killing viruses are a promising therapy for incurable brain tumors, but their effectiveness has been limited in part because immune cells rapidly move in and eliminate them.

27 Nov 2007

BioMarin files investigational NDA for PEG-PAL for the treatment of phenylketonuria

BioMarin Pharmaceutical Inc. has announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL (Poly Ethylene Glycol-Phenylalanine Ammonia Lyase), formerly known as Phenylase, for the treatment of phenylketonuria (PKU).

27 Nov 2007

Australian scientist awarded $1 million by Pfizer Australia to develop gene therapies for muscle-related diseases

An Australian scientist has been awarded a $1 million research grant to develop innovative gene therapy tools for muscle-related diseases.

27 Nov 2007

Cholera can be controlled with oral vaccines

Endemic cholera, a potentially fatal diarrheal disease found in the world's most impoverished countries, could be effectively controlled by orally vaccinating half of the affected populations once every two years for only pennies per dose, according to new findings by an international team of researchers led by Ira M. Longini Jr., Ph.D., a biostatistician in the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center in Seattle. Longini and colleagues will report their findings online Nov. 27 in PLoS Medicine.

27 Nov 2007

Australian researcher heralds a golden age in biomedical science

A senior University of Sydney researcher has heralded a 'golden age' of modern biochemistry and molecular biology brought about by our complete sequencing of the human genome.

27 Nov 2007

Experimental gene therapy trial for arthritis allowed to resume

Trials in the U.S. of a controversial and experimental gene therapy have been given the green light to resume following the tragic death of a volunteer in July.

27 Nov 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

Researchers transfer immune response to myeloma patient

Researchers at the University of Arkansas for Medical Sciences (UAMS) have for the first time transferred an immune response in a healthy individual to a patient with multiple myeloma, a cancer of the bone marrow, showing promise for cancer vaccination.

27 Nov 2007